Customized disease-specific genomic test tailored for Bladder, Breast, Colon, Gl, Lung, Melanoma, Ovary, Prostate, Rectal, and Thyroid

Improving Accessibility:

OncoTarget® improves accessibility of genomic tests

Targeted treatment recommendation:

The test recommends available treatment and clinical trials beneficial for the patient in the tested genes.

Swift Results:

The test offers quick and easily comprehensible results.

Affordable:

OncoTarget® is an affordable genomic test with good coverage of disease-specific genes.

OncoTarget™ is cutting edge NGS Panel designed to identify targeted mutations in Bladder, Breast, Colon, GI, Lung, Melanoma, Ovary, Prostate, Rectal and Thyroid.

What is OncoTarget?

Common Cancers & key targetable genes

Indicates selected genes tested in ten solid tumors from OncoTarget™

Current Challenges in Genomic Profiling

• Lack of awareness and accessibility

• High cost

• Long turnaround time (TAT)

  • Genomic Alteration – detected or Not detected

  • Circulating Tumor Cells (CTC) assesment by OncoDiscover™

  • Programmed Cell Death Ligand-1 (PD-L1) on CTC

Test Outcomes

Note : PD-L1 expression on tissue as an add-on option if requested

With the power of iCare -

The virtual genomics lab for oncologists.

  • AI-powered tool for clinicians to interpret complex genomic (NGS) data

  • Visualise genomic variants in real-time from raw data

  • Access interactive genomic reporting

  • Access rich database of reference literature

  • Enables conduct of molecular tumor board

  • Secure and end-to-end encrypted

Important Features of OncoTarget™

  • Covers all types of genomic alterations such as single nucleotide variants (SNVs), small insertions and deletions (INDELs), copy number variation (CNV), and selected translocations (Fusion) on the selected genes.

  • CTC enumeration for longitudinal monitoring.

  • Enables Artificial Intelligence, AI-powered dynamic reporting through iCARE.

  • Mean depth of 1000x.

  • Mean coverage of 98-100% across all included genes.

Note: 1 FFPE tissue block with 20 – 30 % tumor content (not more than 3-4 months old)

  • Affordable genomic test with deep coverage of disease-specific guideline recommended genes.

  • CTC assessment from blood for longitudinal monitoring.

  • Quick and easily comprehensible results.

  • Improves accessibility of genomic tests.

Benefits of OncoTarget™